dexamethasone injection / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

48 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dexamethasone injection / Generic mfg.
UPFRONT, NCT00507416: Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone

Checkmark P3 data at ASH 2011 in MM
Nov 2011 - Nov 2011: P3 data at ASH 2011 in MM
Checkmark P3 data at ASH 2011 in MM
Nov 2011 - Nov 2011: P3 data at ASH 2011 in MM
Completed
3b
502
US
Bortezomib, Velcade, Dexamethasone, Melphalan, Prednisone, Thalidomide
Millennium Pharmaceuticals, Inc.
Multiple Myeloma
03/13
03/13
NCT00344422: Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Completed
3
198
US
Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Multiple Myeloma, Myeloma, M-Protein, Myeloma Proteins
 
06/04
NCT00080444 / 2014-004603-78: Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)

Completed
3
50
US
aprepitant, ondansetron, dexamethasone, placebo to aprepitant, placebo to dexamethasone, rescue medication
Merck Sharp & Dohme LLC
Vomiting
09/06
03/07
NCT00366834 / 2006-000781-37: Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting

Completed
3
1840
US, Canada, Europe, RoW
Casopitant (GW679769) oral tablets, Casopitant (GW679769) intravenous, Dexamethasone intravenous, Ondansetron oral tablets, placebo
GlaxoSmithKline
Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced
10/07
10/09
NCT00272285: A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea

Completed
3
287
RoW
Ramosetron, Granisetron
Astellas Pharma Inc, Astellas Pharma Taiwan, Inc.
Vomiting, Nausea
12/07
03/08
NCT00168324 / 2004-002496-17: A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

Completed
3
599
Canada, US, Europe, RoW
700 µg Dexamethasone, Posurdex®, 350 µg Dexamethasone, Sham Injection
Allergan
Macular Edema, Retinal Vein Occlusion
03/08
10/08
NCT00168298 / 2004-002502-29: A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

Completed
3
668
Canada, US, Europe, RoW
700 µg Dexamethasone, Posurdex®, 350 µg Dexamethasone, Sham Injection
Allergan
Macular Edema, Retinal Vein Occlusion
03/08
09/08
NCT00343460 / 2007-005068-29: APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

Checkmark From StudyC2006
Feb 2016 - Feb 2016: From StudyC2006
Completed
3
1428
US
APF530, dexamethasone, Palonosetron Hydrochloride, placebo
Heron Therapeutics
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
09/08
02/09
NCT00891761: A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy

Withdrawn
3
0
US, Canada
Dexamethasone, IV casopitant (placebo), IV casopitant (active), Ondansetron
GlaxoSmithKline
Cancer, Chemotherapy-Induced Nausea and Vomiting, Nausea and Vomiting, Solid Tumor Cancer
07/10
07/10
ET743-OVA-301, NCT00113607 / 2004-005276-16: An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

Completed
3
672
US, Canada, Europe, RoW
Trabectedin, Yondelis, DOXIL, CAELYX, Dexamethasone
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., PharmaMar
Ovarian Cancer
11/10
11/10
COMRADE-B, NCT01396057 / 2011-001019-30: Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)

Completed
3
244
Europe
Ranibizumab, Dexamethasone Implant, Sham injection
Novartis Pharmaceuticals
Visual Impairment, Macular Edema, Branch Retinal Vein Occlusion
06/13
06/13
COMRADE-C, NCT01396083 / 2011-001020-38: Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)

Checkmark ARVO 2016: COMRADE
Mar 2016 - Mar 2016: ARVO 2016: COMRADE
Completed
3
243
Europe
Ranibizumab, Dexamethasone implant and sham injections
Novartis Pharmaceuticals
Visual Impairment, Macular Edema, Central Retinal Vein Occlusion
01/14
01/14
NCT01500213 / 2010-022743-37: Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy

Completed
3
555
US
Rolapitant, Varubi, Granisetron, Kytril, Granisol, Dexamethasone, Decadron, Placebo, Placebo to match Rolapitant
Tesaro, Inc.
Chemotherapy-induced Nausea and Vomiting
03/14
03/14
NCT01499849 / 2010-022742-25: Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy

Completed
3
532
US
Rolapitant, Varubi, Granisetron, Kytril, Granisol, dexamethasone, Decadron, Placebo, Placebo to match Rolapitant
Tesaro, Inc.
Chemotherapy-induced Nausea and Vomiting
05/14
05/14
NCT00553059: Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer

Completed
3
62
US
dexamethasone, dronabinol, palonosetron hydrochloride, placebo
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Solvay Pharmaceuticals
Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
08/14
08/14
ELOQUENT-2, NCT01239797 / 2010-020347-12: Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Checkmark ASCO 2016
May 2016 - Jun 2016: ASCO 2016
Checkmark EHA 2016
May 2016 - May 2016: EHA 2016
Checkmark ISH 2016
More
Completed
3
646
Europe, Canada, Japan, US, RoW
Lenalidomide, Revlimid®, Dexamethasone, Decadron®, Dexamethasone Intensol®, Dexpak®, Taperpak®, Dexamethasone (Oral), Dexamethasone (IV), Elotuzumab (BMS-901608; HuLuc63)
Bristol-Myers Squibb, AbbVie
Lymphoma, Multiple Myeloma
09/14
04/21
NCT02106494: A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC

Checkmark From MAGIC trial in CINV at SABCS 2015
Dec 2015 - Dec 2015: From MAGIC trial in CINV at SABCS 2015
Checkmark From MAGIC study at ASCO breast cancer symposium
Oct 2015 - Oct 2015: From MAGIC study at ASCO breast cancer symposium
Checkmark Heron Therapeutics announced positive results from P3 MAGIC study of SUSTOL
More
Completed
3
942
US
APF530, Ondansetron, Ondansetron placebo, APF530 placebo, Fosaprepitant, Dexamethasone
Heron Therapeutics
Chemotherapy-induced Nausea and Vomiting
05/15
05/15
2005-000137-37: Single Dose, Randomized, Double-Blind, Parallel Group, Multicenter Study of Palonosetron 0.25 mg, 0.50 mg and 0.75 mg Administered by the Oral Route versus Palonosetron 0.25 mg IV for the Prevention of Moderately Emetogenic Chemotherapy-Induced Nausea and Vomiting in Patients with Cancer

Completed
3
120
Europe
Palonosetron Softgel Capsules, Aloxi, Dexamethasone sodium phosphate 4mg/1mL injection, Aloxi, Dexamethasone sodium phosphate 4mg/1mL injection, Aloxi, Dexamethasone sodium phosphate 4mg/1mL injection
Helsinn Healthcare SA
Moderately emetogenic chemotherapy induced nausea and vomiting
 
08/06
NCT02519842: Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)

Terminated
3
75
NA
Fosaprepitant, EMEND for injection®, Placebo for fosaprepitant, Ondansetron, Zofran®, Dexamethasone, 5-HT3 antagonist
Merck Sharp & Dohme LLC
Chemotherapy-induced Nausea and Vomiting
02/17
02/17
A.R.R.O.W, NCT02412878 / 2014-005325-12: Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma

Checkmark Data from ARROW study for RRMM at ASH 2018
Dec 2018 - Dec 2018: Data from ARROW study for RRMM at ASH 2018
Checkmark In relapsed & refractory multiple myeloma patients
Oct 2017 - Oct 2017: In relapsed & refractory multiple myeloma patients
Completed
3
478
Europe, Canada, Japan, US, RoW
Carfilzomib, PR-171, PR171, Kyprolis® (carfilzomib) for Injection, Dexamethasone
Amgen
Multiple Myeloma
06/17
01/19
ALCYONE, NCT02195479 / 2014-002272-88: A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Checkmark OS data from ALCYONE trial in combination with Velcade for multiple myeloma at ASH 2019
Dec 2019 - Dec 2019: OS data from ALCYONE trial in combination with Velcade for multiple myeloma at ASH 2019
Checkmark First OS results from the ALCYONE study in 1L multiple myeloma at ASH 2019
Dec 2019 - Dec 2019: First OS results from the ALCYONE study in 1L multiple myeloma at ASH 2019
Checkmark ALCYONE data in previously untreated multiple myeloma at ASH 2018 [screenshot]
More
Active, not recruiting
3
706
Europe, Japan, US, RoW
Velcade, Melphalan, Prednisone, Daratumumab IV, Dexamethasone, Daratumumab SC
Janssen Research & Development, LLC
Multiple Myeloma
11/17
06/24
NCT01846611 / 2012-004808-34: A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Completed
3
581
US, Europe, RoW
Trabectedin, DOXIL, Dexamethasone
Janssen Research & Development, LLC, PharmaMar
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
01/18
11/18
AMN Study, NCT03143049: Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma

Unknown status
3
120
Japan, RoW
PCD, PD
National University Hospital, Singapore, Celgene, International Myeloma Foundation
Relapse Multiple Myeloma
06/18
06/22
NCT03029234: Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma

Completed
3
126
RoW
Dexamethasone, Carfilzomib, Kyprolis
Amgen, Onyx Therapeutics, Inc.
Relapsed and Refractory Multiple Myeloma
11/18
06/21
CANDOR, NCT03158688 / 2016-003554-33: Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

Checkmark Primary analysis results from CANDOR trial for r/r multiple myeloma at ASH 2019
Dec 2019 - Dec 2019: Primary analysis results from CANDOR trial for r/r multiple myeloma at ASH 2019
Checkmark From CANDOR trial in combination with carfizomib & dexamethasone for r/r multiple myeloma
Sep 2019 - Sep 2019: From CANDOR trial in combination with carfizomib & dexamethasone for r/r multiple myeloma
Completed
3
466
Europe, Canada, Japan, US, RoW
Dexamethasone, Daratumumab, DARZALEX®, Carfilzomib, KYPROLIS®
Amgen
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
07/19
04/22
NCT03476239: Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Completed
3
121
RoW
Blinatumomab, BLINCYTO®, AMG 103, MT103, Dexamthasone
Amgen
Acute Lymphoblastic Leukemia
08/19
04/21
2020-001333-13: Dexamethasone associated with hydroxychloroquine vs. hydroxychloroquine alone for the early treatment of severe ARDS caused by COVID-19 : a randomized controlled trial Dexaméthasone associée à l'hydroxychloroquine vs. hydroxychloroquine seule dans le traitement précoce des SDRA sévères liés au COVID-19 : un essai randomisé et contrôlé

Ongoing
3
122
Europe
DEXAMETHASONE, HYDROXYCHLOROQUINE, Injection, Tablet, DEXAMETHASONE MYLAN 20mg/5mL, PLAQUENIL 200MG
Groupe Hospitalier Paris Saint-Joseph, Groupe Hospitalier Paris Saint-Joseph
Acute Respiratory Distress Syndrome (ARDS) caused by SARS-Cov-2 infection Syndrome de Détresse Respiratoire Aiguë (SDRA) lié à l'infection par SARS-Cov-2, Acute respiratory distress syndrome caused by SARS-Cov-2 infection Syndrome de détresse respiratoire aiguë lié à l'infection par SARS-Cov-2, Diseases [C] - Virus Diseases [C02]
 
 
ELO 1 Substudy, NCT01891643 / 2010-022445-20: PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma

Terminated
3
23
Europe, US
Lenalidomide, Revlimid®, Dexamethasone, Decadron®, Dexamethasone Intensol®, Dexpak®, Taperpak®, Elotuzumab, BMS-901608
Bristol-Myers Squibb, Abbott
Newly Diagnosed, Previously Untreated Multiple Myeloma
06/20
06/20
CODEX, NCT04327401: COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III

Terminated
3
299
RoW
Dexamethasone, Decadron, Dexasone, Diodex, Hexadrol, Maxidex
Hospital Sirio-Libanes, Hospital Israelita Albert Einstein, Hospital do Coracao, Brazilian Research In Intensive Care Network, Ache Laboratorios Farmaceuticos S.A.
Coronavirus Infection, Pneumonia, Viral, Acute Respiratory Distress Syndrome
07/20
07/20
NCT03664674 / 2018-001464-35: Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease

Completed
3
148
Europe, US, RoW
OTO-104, Placebo
Otonomy, Inc.
Meniere Disease
12/20
12/20
NCT02703272 / 2016-000259-28: A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Terminated
3
72
Europe, Canada, US, RoW
Ibrutinib, Rituximab, Ifosfamide, Carboplatin, Etoposide, Vincristine, Idarubicin, Dexamethasone
Janssen Research & Development, LLC, Pharmacyclics LLC.
Lymphoma, Non-Hodgkin
06/21
06/21
IKEMA, NCT03275285 / 2017-001940-37: Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

Checkmark PFS data from IKEMA trial in combination with carfilzomib and dexamethasone for 2L multiple myeloma
May 2022 - May 2022: PFS data from IKEMA trial in combination with carfilzomib and dexamethasone for 2L multiple myeloma
Checkmark Detailed data from P3 IKEMA trial in combination with carfilzomib and dexamethasone for r/r multiple myeloma
Jun 2020 - Jun 2020: Detailed data from P3 IKEMA trial in combination with carfilzomib and dexamethasone for r/r multiple myeloma
Checkmark From IKEMA trial in combination with carfilzomib and dexamethasone at ASCO 2020
More
Active, not recruiting
3
302
Europe, Canada, Japan, US, RoW
isatuximab SAR650984, Sarclisa, carfilzomib, Kyprolis, dexamethasone
Sanofi
Plasma Cell Myeloma
01/22
11/24
EXCELLENCE, NCT04123561: Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain

Completed
3
506
US, RoW
TLC599, TLC599 Injection, DSP, Dexamethasone Sodium Phosphate, Normal Saline
Taiwan Liposome Company
Osteoarthritis of the Knee
02/22
02/22
2021-003284-10: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Not yet recruiting
3
750
Europe, RoW
Bortezomib, Dexamethasone, Ciltacabtagene Autoleucel, Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20), Lenalidomide, JNJ-68284528, JNJ-54767414, Powder for solution for injection, Coated tablet, Dispersion for infusion, Injection, Capsule, hard, Solution for injection, VELCADE, Dexamethasone, CARVYKTI, lenalidomide accord, DARZALEX
Stichting European Myeloma Network (EMN), European Myeloma Network (EMN), Janssen-Cilag International NV
Multiple Myeloma, Newly diagnosed multiple myeloma, Diseases [C] - Cancer [C04]
 
 
RESET, NCT05187793: Study of Efficacy of Different Treatment Regimens of Olokizumab

Active, not recruiting
3
198
RoW
Olokizumab, Standard therapy
R-Pharm, Federal Budget Institution of Science "Central Research Institute of Epidemiology" of the Rospotrebnadzor, Group of companies Medsi, JSС
COVID-19
10/22
04/23
EARLYDEXCoV2, NCT04836780: DEXamethasone EARLY Administration in Hospitalized Patients With Covid-19 Pneumonia

Recruiting
3
126
Europe
Dexamethasone, Dexametasona kern pharma solution for injection 4 mg/ml
Hospital Universitario Infanta Leonor, Fundación para la Investigación e Innovación Biomédica del Hospital Universitario Infanta Leonor, Kern Pharma, S.L.
COVID-19, Acute Respiratory Distress Syndrome, Pneumonia, Viral
02/23
03/23
Neptuno, NCT04784559 / 2020-005951-19: Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection

Terminated
3
205
Europe, RoW
Plitidepsin, Dexamethasone, Remdesivir, Favipiravir
PharmaMar
COVID-19 Infection
03/23
03/23
Ocarina II, NCT05232825 / 2020-005448-48: A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

Hourglass Jan 2023 - Dec 2023 : Data from Ocarina II trial for multiple sclerosis
Hourglass Apr 2022 - Jul 2022 : First patient in of P3 Ocarina II trial for multiple sclerosis
Active, not recruiting
3
236
Europe, US, RoW
Ocrelizumab IV, RO4964913, Ocrelizumab SC, Methylprednisolone IV, Diphenhydramine IV, Dexamethasone given orally, Desloratadine given orally
Hoffmann-La Roche
Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
04/25
04/25
NCT05509634: Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors

Completed
3
754
RoW
HR20013 for injection；dexamethasone, fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone
Fujian Shengdi Pharmaceutical Co., Ltd.
Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
06/23
08/23
MonumenTAL-6, NCT06208150: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Recruiting
3
795
Europe, Canada, Japan, RoW
Talquetamab, JNJ-64407564, Talvey, Pomalidomide, Pomalyst, Imnovid, Teclistamab, JNJ-64007957, Tecvayli, Elotuzumab, Empliciti, Dexamethasone, Bortezomib, Velcade
Janssen Research & Development, LLC
Relapsed or Refractory Multiple Myeloma
04/26
06/30
MajesTEC-3, NCT05083169 / 2020-004742-11: A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

Active, not recruiting
3
587
Europe, Canada, Japan, US, RoW
Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Teclistamab, JNJ-64007957
Janssen Research & Development, LLC, Janssen Research & Development, LLC
Multiple Myeloma
08/25
12/28
NCT05438043: A Study of Daratumumab

Recruiting
3
500
Europe, US, RoW
Daratumumab, JNJ-54767414, Carfilzomib, Dexamethasone, Lenalidomide, Pomalidomide
Janssen Research & Development, LLC
Multiple Myeloma
01/26
04/26
MonumenTAL-3, NCT05455320 / 2021-000202-22: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

Recruiting
3
810
Europe, Japan, US, RoW
Talquetamab, JNJ-64407564, Daratumumab, Pomalidomide, Dexamethasone
Janssen Research & Development, LLC, Janssen Research & Development, LLC
Relapsed or Refractory Multiple Myeloma
02/26
09/29
IMROZ, NCT03319667 / 2017-002238-21: Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant

Calendar Jan 2024 - Dec 2024: Submission for newly diagnosed multiple myeloma (based on IMROZ trial)
Hourglass Oct 2023 - Dec 2023 : Pivotal data readout from IMROZ trial for 1L multiple myeloma
Hourglass Oct 2021 - Mar 2022 : Regulatory submissions for NDMM (based on IMROZ trial) in EU
Hourglass Jan 2021 - Dec 2021 : Primary data from IMROZ trial for newly diagnosed multiple myeloma
Active, not recruiting
3
475
Europe, Japan, US, RoW
Isatuximab SAR650984, Sarclisa, Bortezomib, Velcade®, Lenalidomide, Dexamethasone
Sanofi
Plasma Cell Myeloma
04/26
06/27
ITHACA, NCT04270409 / 2019-003139-47: A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma

Active, not recruiting
3
337
Europe, Canada, Japan, US, RoW
Isatuximab SAR650984, Sarclisa, Lenalidomide, Dexamethasone, Montelukast or equivalent, Acetaminophen, Diphenhydramine or equivalent, Methylprednisolone or equivalent
Sanofi
Plasma Cell Myeloma
11/30
10/33
NCT00333814 / 2006-000736-26: A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis

Completed
2/3
229
US, Canada, Europe, RoW
Dexamethasone, Posurdex®, dexamethasone, Sham injection
Allergan
Intermediate Uveitis, Posterior Uveitis
12/08
04/09
NCT05546359: Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients

Recruiting
2/3
410
Europe, Canada, US
Amisulpride Injection, Barhemsys, Dexamethasone, Decadron
Acacia Pharma Ltd, Amicus CD LLC, Premier Research Group plc
Nausea and Vomiting, Postoperative
06/25
12/25
NCT06212336: ISTH/ANRS 0409s INTEGRATE Lassa Fever Study

Not yet recruiting
2/3
1755
NA
Favipiravir, Ribavirin, Standard of care, Dexamethasone
Irrua Specialist Teaching Hospital, Alliance for International Medical Action, University of Bordeaux, Bernhard Nocht Institute for Tropical Medicine, Federal Medical Centre, Owo, Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire, Fondation pour la Recherche Scientifique, Benin, Médecins Sans Frontières, Belgium, Alex Ekwueme Federal University Teaching Hospital, Donka Hospital, Conakry, Centre de Recherche Médicale de Lambaréné, University of Hamburg-Eppendorf, Phebe Hospital, Liberia, University of North Carolina, ANRS, Emerging Infectious Diseases
Lassa Fever
06/27
06/27

Download Options